MedTrace Logo

A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System

NCT02370303 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2018-03-21

No results posted yet for this study

Summary

The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.

Conditions

  • Lung Cancer
  • Lung Neoplasms
  • Cancer of Lung
  • Cancer of the Lung
  • Neoplasms, Lung
  • Neoplasms, Pulmonary
  • Pulmonary Cancer
  • Pulmonary Neoplasms
  • Carcinoma, Non-small-cell Lung
  • Adenocarcinoma
  • Squamous Cell Carcinoma

Sponsors & Collaborators

  • Clearbridge Biomedics

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Dennis Wigle, MD, PhD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-07-09
Completion
2016-07-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370303 on ClinicalTrials.gov